BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/6/2020 7:36:12 AM | Browse: 1323 | Download: 2527
Publication Name World Journal of Gastroenterology
Manuscript ID 58599
Country United States
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Review
Article Title Efficacy and safety of anti-hepatic fibrosis drugs
Manuscript Source Invited Manuscript
All Author List Konstantinos Damiris, Zaid H Tafesh and Nikolaos Pyrsopoulos
ORCID
Author(s) ORCID Number
Konstantinos Damiris http://orcid.org/0000-0001-9972-740X
Zaid H Tafesh http://orcid.org/0000-0002-3927-9569
Nikolaos Pyrsopoulos http://orcid.org/0000-0002-6950-8174
Funding Agency and Grant Number
Corresponding Author Nikolaos Pyrsopoulos, FACP, MD, PhD, Director, Director, Doctor, Doctor, Professor, Medicine-Gastroenterology and Hepatology, Rutgers-New Jersey Medical School, 185 S. Orange Avenue, MSB H-535, Newark, NJ 07103, United States. pyrsopni@njms.rutgers.edu
Key Words Liver; Fibrosis; Cirrhosis; Antifibrotic; Pharmacotherapy; Clinical trial
Core Tip A number of clinical trials have targeted various etiologies of liver fibrosis and cirrhosis. Some have been promising, particularly in metabolic associated fatty liver disease and viral hepatitis. Results from these studies have shown that there are safe treatments available, forming currently practiced therapeutic guidelines, and shining light on the potential reversibility of liver fibrosis and cirrhosis caused by a variety of etiologies.
Publish Date 2020-11-06 07:36
Citation Damiris K, Tafesh ZH, Pyrsopoulos N. Efficacy and safety of anti-hepatic fibrosis drugs. World J Gastroenterol 2020; 26(41): 6304-6321
URL https://www.wjgnet.com/1007-9327/full/v26/i41/6304.htm
DOI https://dx.doi.org/10.3748/wjg.v26.i41.6304
Full Article (PDF) WJG-26-6304.pdf
Full Article (Word) WJG-26-6304.docx